Allspring Global Investments Holdings LLC Cuts Stock Position in Haemonetics Corporation $HAE

Allspring Global Investments Holdings LLC lessened its stake in shares of Haemonetics Corporation (NYSE:HAE) by 11.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 939,727 shares of the medical instruments supplier’s stock after selling 121,063 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Haemonetics were worth $75,159,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Federated Hermes Inc. raised its position in shares of Haemonetics by 1,405.7% in the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after purchasing an additional 43,042 shares during the last quarter. Harbor Capital Advisors Inc. increased its stake in Haemonetics by 49.7% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 42,859 shares of the medical instruments supplier’s stock valued at $2,089,000 after purchasing an additional 14,226 shares in the last quarter. Isthmus Partners LLC raised its holdings in Haemonetics by 36.5% in the third quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after buying an additional 16,505 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its holdings in Haemonetics by 36.2% in the third quarter. Fort Washington Investment Advisors Inc. OH now owns 706,312 shares of the medical instruments supplier’s stock worth $34,426,000 after buying an additional 187,630 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Haemonetics in the second quarter worth approximately $36,822,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Haemonetics Trading Up 2.6%

NYSE:HAE opened at $56.34 on Wednesday. The business has a fifty day moving average price of $61.65 and a 200-day moving average price of $65.09. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 15.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.28.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analysts’ expectations of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.19 earnings per share. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

HAE has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research note on Friday, February 6th. Robert W. Baird set a $81.00 price target on Haemonetics in a report on Friday, February 6th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Citigroup lowered their price objective on shares of Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 11th. Finally, JPMorgan Chase & Co. increased their price target on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $83.89.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.